U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852573) titled 'Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus' on Feb. 18.
Brief Summary: This is an open, single-arm, phase I clinical study of ZM001 in patients with refractory systemic lupus erythematosus
Study Start Date: Feb. 20
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
BIOLOGICAL: ZM001 Injection
ZM001 injection, 2.5x 10^7 CAR-T cells, 5x 10^7 CAR-T cells, 1x 10^8 CAR-T cells and 2x 10^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m^2 (D-5~D-3), determined by tumor burden at baseline. Drug: Cyclophosphami...